First agreement for oral variant of the device, which is already approved and marketed for a nasally delivered product
Consort Medical, the owner of UK drug delivery device specialist Bespak and pharmaceutical CDMO Aesica, has signed a significant commercial supply agreement for its proprietary integrated dose counter (IDC) system with an unnamed pharmaceutical client.
The multi-year supply agreement covers the supply of both the IDC actuator and the pressurised metered dose inhaler (pMDI) valve.
Consort says this IDC programme is the first commercial oral variant of the device, which is already approved and marketed for a nasally delivered product.
Dose-counting devices fulfil an important patient and compliance need to let patients know if their device contains sufficient drug and to indicate when they need to seek a further prescription. It provides patients with a reliable, easy to read indication of how many doses are left inside the canister in line with US FDA guidance.
The device will be manufactured at the Bespak IDC facility in Norfolk
Jonathan Glenn, Consort Medical’s Chief Executive Officer, said the company has a long history of excellence, reliability and innovation enabling pharmaceutical companies to implement drug delivery technologies that can streamline and accelerate the route to market for their drugs.
'With the conclusion of this agreement for our IDC device we have reinforced the ongoing strength of our respiratory device franchise, in particular in the pMDI segment, and created a significant business opportunity,' he said.
The device will be manufactured at Bespak’s IDC facility at King’s Lynn, Norfolk. The project will be referred to as (IDC300).